One such drug is tamoxifen (TAM), which can successfully shut down ER activation and downregulate the growth of ER + tumors (Early Breast Cancer Trialists’ Collaborative Group EBCTCG, 2011). This evidence concerns the gene ESR1 and breast cancer.